DRC: Four vaccines against the Bundibugyo strain are being trialled, offering scientific hope for containing Ebola
The fight against the Ebola virus disease in the Democratic Republic of Congo is advancing on the scientific front. In Bunia, in Ituri province, Dr. Chikwe Ihekweazu, Executive Director of the World Health Organization’s Health Emergencies Programme, announced that four vaccine candidates targeting the Bundibugyo strain are currently in the clinical trial phase.
According to the WHO official, this research is progressing encouragingly thanks to the mobilization of international scientific partners involved in the response.
The research teams consider the trial conditions satisfactory and are closely monitoring the evolution of results.
If the data continue to meet scientific expectations, possible vaccine availability is envisioned in approximately three months a prospect that would represent a major breakthrough in strengthening the means to combat the disease in the DRC.
Despite this vaccine hope, WHO emphasizes that the response remains based on already proven field tools.
Rapid case detection, systematic contact tracing, and the organization of safe and dignified burials remain essential to curb transmission. Potential vaccines would complement, not replace, these operational measures.
Dr. Ihekweazu stressed the importance of community engagement. The trust and collaboration of local populations remain determining factors for the effectiveness of health interventions and the success of clinical trials.
The teams present in Ituri are therefore continuing both research and awareness-raising and care activities.
Ituri remains the main epicenter of the epidemic, where health services and their partners are intensifying efforts to contain the spread. This announcement comes as the DRC faces its 17th Ebola outbreak. According to the latest official figures, the country has recorded 1,759 confirmed cases, 600 deaths, and nearly 750 recoveries since the start of the epidemic.
Between scientific hopes and operational imperatives, health authorities and WHO are pursuing a dual strategy: accelerating vaccine research while maintaining and strengthening the prevention measures essential to protect populations.
